Results 61 to 70 of about 49,641 (173)

Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study

Journal of Microbiology, Immunology and Infection
Background: Remdesivir has been used to treat severe coronavirus 2019 (COVID-19); however, its safety and effectiveness in patients remain unclear. This study aimed to investigate the safety and effectiveness of remdesivir in patients with COVID-19 with ...
Yan-Bo Huang, Chip-Jin Ng, Cheng-Hsun Chiu, Chung-Hsien Chaou, Shi-Ying Gao, Shou-Yen Chen   +5 more
doaj   +1 more source

Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study

Scientific Reports, 2022
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan.
Kazuhito Miyazaki, Yukihiro Yoshimura, Nobuyuki Miyata, Hiroaki Sasaki, Aya Shiba, Masaharu Aga, Yusuke Hamakawa, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Tsuneo Shimokawa, Hiroaki Okamoto, Natsuo Tachikawa   +12 more
doaj   +1 more source

Remdesivir interactions with sulphobutylether-β-cyclodextrins: a case study using selected substitution patterns [PDF]

, 2022
Modified cyclodextrins (CDs) consist of a distribution of different structures with different number and location of the substituted groups. Among the most important applications of these molecules is their use as an enabling excipient in pharmaceutical ...
Antle, Vince, García Fandiño, Rebeca, Pipkin, James, Piñeiro Guillén, Ángel   +3 more
core   +1 more source

The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis

Case Reports in Infectious Diseases, 2020
Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials.
Vincent Peyko, Helena Ladd, Anthony Cutrona   +2 more
doaj   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

The Impact of Covid-19 on Future Higher-Age Mortality [PDF]

, 2020
Covid-19 has predominantly affected mortality at high ages. It kills by inflaming and clogging the air sacs in the lungs, depriving the body of oxygen ‒ inducing hypoxia ‒ which closes down essential organs, in particular the heart, kidneys and liver ...
Blake, D., Cairns, A. J. G., Kessler, A.R., Kessler, M.   +3 more
core  

Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. [PDF]

, 2020
BackgroundThe US Food and Drug Administration issued an Emergency Use Authorization for remdesivir use in patients with severe COVID-19.MethodsWe utilized data from 2 quaternary acute care hospitals. The outcomes of interest were the impact of remdesivir
Aridi, Jad, Aung, Su, Beckwith, Curt G, Byrd, Katrina M, Farmakiotis, Dimitrios, Flanigan, Timothy P, Garland, Joseph M, Johnson, Jennie E, Kalligeros, Markos, Larkin, Jerome, Macias Gil, Raul, Mylona, Evangelia K, Mylonakis, Eleftherios, Neill, Marguerite, O'Brien, Thomas, Pandita, Aakriti, Rybak, Natasha, Sanchez, Martha, Shehadeh, Fadi, Tashima, Karen T   +19 more
core   +1 more source

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Case Reports in Women's Health, 2020
Summary: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus ...
Jonathon Anderson, Jordan Schauer, Suzanne Bryant, Cornelia R. Graves   +3 more
doaj   +1 more source

Safety and heart rate changes in Covid-19 patients treated with Remdesivir

International Journal of Infectious Diseases, 2021
Objectives: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir.
Natale Daniele Brunetti, MD, PhD, Mariacristina Poliseno, MD, Irene Francesca Bottalico, MD, Antonio Centola, MD, Laura Montemurro, MD, Salvatore Sica, MD, Teresa Santantonio, MD, Sergio Lo Caputo, MD   +7 more
doaj   +1 more source

ProTides for Antiviral Activity Beyond Liver Cells

Chemistry – A European Journal, EarlyView.
A strategy for obtaining prodrugs of antiviral nucleotides with broad tissue activity is presented that relies on cycloalkyl or cycloalkylalkyl esters, improving uptake and esterase cleavage, and producing nanomolar inhibitors in kidney, colon, and lung cells.
Felix Goebel, Adrian Humboldt, Heeyoung Kim, Carl J. M. Schölzel, Ralf Bartenschlager, Clemens Richert   +5 more
wiley   +1 more source